Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 18, 2004. The document primarily reports on corporate governance matters, specifically the results of the Annual General Meeting (AGM) held on May 17, 2004, changes to Board Committee memberships, and updates regarding Directors' interests in company shares.
Key Financial Metrics
The filing text does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document focuses exclusively on governance and shareholder voting data.
Material Changes and Corporate Actions
- AGM Results: All 12 resolutions presented at the AGM were passed by shareholders. Notable vote percentages included 98.61% for the adoption of Financial Statements and 89.49% for the Approval of the Remuneration Report.
- Board Committee Changes:
- Remuneration Committee: Sir Robert Wilson appointed Chairman, succeeding Mr. McArthur who is retiring.
- Nominations Committee: Dr. Ronaldo Schmitz appointed as a member.
- Corporate Responsibility Committee: Sir Christopher Hogg appointed Interim Chairman following Mr. McHenry's retirement; Sir Ian Prosser appointed as a member.
- Directors' Interests:
- Mr. J.D. Coombe acquired 22 Ordinary Shares (11 personal, 11 company match) under the ShareReward Plan at £11.70 per share on May 12, 2004.
- The GSK US Retirement Savings Plan saw a decrease in Ordinary Share ADRs from 18,870,513 to 18,866,129 on May 14, 2004, at an average price of $41.95.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of specific business risks and contingencies. Chairman Sir Christopher Hogg commented only on the successful passage of AGM resolutions, noting they were passed by a "substantial majority."
Investor Verification Checklist
- Verify the full text of the 2003 Annual Report and Financial Statements referenced in Resolution 1, as this filing only confirms their adoption.
- Review the specific terms of the ShareReward Plan to understand the mechanics of the Director share acquisitions.
- Confirm the effective dates of the new Board Committee chairmanships and memberships for governance compliance.
- Check subsequent filings for the detailed financial results of the 2003 fiscal year, as they are not included in this 6-K.